Cost of Mounjaro, Wegovy, Zepbound, and Ozempic: Full 2025 Price Breakdown

What Does Mounjaro Cost Without Insurance?

Mounjaro (tirzepatide, Eli Lilly) carries a list price of approximately $1,069 per month regardless of dose. That single price covers every strength from 2.5 mg through 15 mg, which differs from how most medications are priced and matters for patients escalating from starter to maintenance doses. Patients paying cash at a retail pharmacy without any coupon will see that number on their receipt.

The drug received FDA approval in May 2022 for type 2 diabetes management. Because the obesity indication belongs to Zepbound (the same molecule, different brand), insurers covering Mounjaro typically require a type 2 diabetes diagnosis. Prescribing Mounjaro off-label for weight loss in a patient without diabetes creates a much harder prior-authorization battle and usually results in a full cash-pay scenario.

Eli Lilly runs a savings card program for commercially insured patients that can reduce out-of-pocket cost to as low as $25 per fill. Uninsured or underinsured patients may qualify for the Lilly Insulin Value Program or Lilly Cares Foundation assistance, both of which apply income thresholds. Calling 1-800-545-5979 before the first fill is worth the 10 minutes.

SURMOUNT-2 (N=938, tirzepatide in adults with type 2 diabetes and obesity) demonstrated a 15.7% mean body weight reduction at 72 weeks on the 15 mg dose versus 3.3% with placebo, published in The Lancet [1]. That efficacy data reinforces why physicians and patients are willing to manage the cost question rather than abandon the drug.

What Does Zepbound Cost Without Insurance?

Zepbound (tirzepatide for obesity, Eli Lilly) lists at approximately $1,059 per month, fractionally less than Mounjaro for the same active compound. The FDA approved Zepbound in November 2023 specifically for chronic weight management in adults with a BMI of 30 or greater, or BMI of 27 or greater with at least one weight-related comorbidity, per the Zepbound FDA label [2].

LillyDirect offers single-dose vials of Zepbound directly to patients for $399 per month (for doses up to 7.5 mg) or $549 per month (for 10 mg through 15 mg) as of mid-2025. These vials require self-injection with a separate syringe, which some patients find less convenient than the autoinjector pen. The trade-off for many is straightforward: $660 in annual savings per patient at the lower tier.

SURMOUNT-1 (N=2,539) showed a mean body weight reduction of 22.5% at 72 weeks with tirzepatide 15 mg versus 2.4% with placebo (P<0.001) [3]. SURMOUNT-4 demonstrated that patients who discontinued tirzepatide regained approximately 14 percentage points of the weight lost over 52 weeks, underscoring that ongoing cost is a long-term planning item, not a one-time purchase [4].

What Does Wegovy Cost Without Insurance?

Wegovy (semaglutide 2.4 mg, Novo Nordisk) lists at approximately $1,349 per month, the highest list price in this drug class. Novo Nordisk's NovoCare savings card program covers commercially insured patients who meet criteria, potentially reducing monthly cost to $0 for up to 12 months. Uninsured patients without qualification for patient assistance face the full list price.

STEP-1 (N=1,961) showed a mean weight reduction of 14.9% at 68 weeks with semaglutide 2.4 mg versus 2.4% with placebo [5]. STEP-5 extended that picture to 104 weeks, showing sustained mean weight loss of 15.2% with continued treatment [6]. Both trials enrolled adults without type 2 diabetes, and the Wegovy FDA label specifies the same BMI thresholds as Zepbound [7].

Commercial insurance coverage for Wegovy varies sharply by employer plan and state mandate. The American Association of Clinical Endocrinologists 2016 obesity guidelines state that pharmacotherapy should be considered for patients who do not achieve weight-loss goals through lifestyle modification alone, which provides clinical grounding for prior-authorization letters [8]. Even with that grounding, roughly 30% of commercial prior-authorization requests for Wegovy are denied on the first submission, according to pharmacy benefit manager data.

What Does Ozempic Cost Without Insurance?

Ozempic (semaglutide for type 2 diabetes, Novo Nordisk) lists at approximately $968 per month. Its approved doses top out at 2 mg weekly for diabetes, below the 2.4 mg weekly approved in Wegovy. Off-label use at 1 mg for weight management is common in clinical practice, but that off-label status complicates coverage.

Novo Nordisk's savings program for commercially insured Ozempic patients may reduce cost to $25 per fill. GoodRx and similar discount platforms can bring cash-pay prices to roughly $850 per month at select pharmacies. Neither option approaches the compounded-drug price tier.

SELECT (N=17,604) showed that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with pre-existing cardiovascular disease and overweight or obesity over a mean follow-up of 34.2 months (HR 0.80 to 95% CI 0.72 to 0.90, P<0.001) [9]. That cardiovascular outcome data has strengthened the case for insurance coverage of semaglutide-class drugs but has not yet produced uniform payer acceptance.

What Does Compounded Tirzepatide or Semaglutide Cost?

Compounded GLP-1 medications occupy a different regulatory and pricing category. Compounded semaglutide or tirzepatide from an FDA-registered 503B outsourcing facility typically costs $199 to $499 per month through licensed telehealth prescribers, depending on dose and provider. That figure is 50% to 80% below brand list prices.

The FDA placed both semaglutide and tirzepatide on its shortage list in 2022 and 2023, respectively, which legally permitted 503A and 503B pharmacies to compound those active pharmaceutical ingredients. As of early 2025, the FDA has begun removing tirzepatide from the shortage list following Eli Lilly's production expansion. Once removed from the shortage list, 503A compounding of a drug that is not on the shortage list and is not for an individual patient-specific reason becomes legally questionable. 503B outsourcing facilities face a separate but similarly narrowing window.

Patients choosing compounded products should confirm three things: the pharmacy holds a current 503B registration with the FDA (searchable at fda.gov), the prescriber is licensed in the patient's state, and the formulation contains the base free-acid or salt form of the active ingredient rather than unauthorized derivatives like tirzepatide acetate. The FDA issued multiple warning letters to compounders in 2024 for using non-equivalent salt forms.

The HealthRX Three-Tier Cost Framework helps patients match their situation to the right access channel:

• Tier 1 (Brand with insurance): Patient has commercial coverage and a qualifying diagnosis. Target out-of-pocket: $0 to $100 per month with manufacturer savings card stacking.
• Tier 2 (Brand cash-pay via manufacturer direct): Patient lacks insurance coverage but meets income or program criteria. LillyDirect Zepbound vials at $399 to $549 per month represent the most accessible option in this tier.
• Tier 3 (Compounded via 503B telehealth): Patient cannot access Tier 1 or Tier 2. Monthly cost $199 to $499, regulatory status subject to FDA shortage-list decisions, and clinical monitoring responsibility falls heavily on the prescribing telehealth provider.

Does Insurance Cover Mounjaro, Wegovy, or Zepbound?

Coverage depends on indication, plan type, and state law. For type 2 diabetes, most commercial plans cover Ozempic and Mounjaro after prior authorization. For obesity without diabetes, coverage is inconsistent and often denied.

Medicare Part D is prohibited by statute from covering drugs approved solely for weight loss. That prohibition, codified in the Social Security Act Section 1860D-2(e), affects roughly 49 million Medicare Part D enrollees. The Treat and Reduce Obesity Act, which would remove that prohibition, has been reintroduced in Congress multiple times but has not passed as of mid-2025.

Medicaid coverage varies by state. As of 2025, fewer than 20 states cover anti-obesity medications under their Medicaid formularies. California, Illinois, and New York are among states that have added some coverage, while most Southern states exclude anti-obesity drugs entirely.

Employer-sponsored plans that voluntarily add obesity drug coverage have seen mixed results. A 2023 analysis in JAMA found that adding GLP-1 obesity coverage to an employer plan increased annual per-member-per-year pharmacy spend by approximately $2,400, creating pressure on smaller employers to limit or exclude the benefit [10].

The SELECT trial's cardiovascular data may shift that calculus. Reduced hospitalizations for MI and stroke in high-risk patients could offset drug acquisition costs over multi-year time horizons, a health-economics argument that patient advocates are presenting to insurers and pharmacy benefit managers.

How Do Savings Programs and Coupons Work?

Manufacturer savings programs are the most reliable cost-reduction option for commercially insured patients. They work through a copay card that pays the difference between what insurance covers and the patient's copay, up to a monthly cap.

Eli Lilly's savings card for Zepbound covers commercially insured patients who meet eligibility criteria, reducing monthly cost to as low as $25. The card explicitly excludes patients using government-funded insurance, including Medicare, Medicaid, TRICARE, and the Federal Employee Health Benefits program. Patients who use the card while enrolled in a government plan risk violating program terms and potentially triggering anti-kickback statute concerns, a point that prescribing physicians should discuss at intake.

Novo Nordisk runs NovoCare for Wegovy. Qualified patients pay as little as $0 per month for the first year. After 12 months, the savings tier resets and the patient must re-enroll or pay a higher copay. Planning the annual re-enrollment is a practical step many patients miss.

GoodRx, RxSaver, and Blink Health function as pharmacy benefit discount cards, not insurance. They negotiate discount rates with retail pharmacies. For Ozempic, GoodRx prices at major chains have ranged from $820 to $1,020 per month. Those prices are below list but still far above compounded or savings-card rates. GoodRx cannot be combined with insurance or manufacturer copay cards at the point of sale.

What Affects Out-of-Pocket Cost the Most?

Insurance status drives the largest cost difference. A commercially insured patient with a savings card may pay $25 per month. An uninsured patient at a retail pharmacy may pay $1,069 for the same prescription. That $1,044 monthly gap represents the broadest cost variable in the GLP-1 drug class.

Dose matters less than expected because Mounjaro, Zepbound, and Wegovy price all doses at a single monthly rate. A patient on 15 mg tirzepatide pays the same list price as a patient on 2.5 mg. For compounded products, dose does affect cost because compounding pharmacies price by milligram content.

Pharmacy choice affects cash-pay prices by up to 15%. Mark Cuban's Cost Plus Drugs (costplusdrugs.com) does not yet carry tirzepatide or semaglutide branded products, but independent pharmacies running 340B programs may offer lower rates to eligible patients.

Prior-authorization appeals take time. A first-round denial adds 30 to 90 days before access. Patients who cannot afford to wait sometimes start with compounded product while appealing brand coverage, then transition to brand once approved.

Compounded vs. Brand: What the Clinical Difference Is

The active molecule in FDA-approved Mounjaro and Zepbound is tirzepatide base. SURMOUNT-1 used that formulation, achieving 22.5% mean weight loss at 72 weeks on 15 mg [3]. Compounded tirzepatide from a 503B facility using pharmaceutical-grade active pharmaceutical ingredient may contain equivalent chemistry, but no head-to-head RCT data exists comparing compounded to brand-name tirzepatide in human subjects.

For semaglutide, STEP-1 (N=1,961) achieved 14.9% weight loss at 68 weeks with brand semaglutide 2.4 mg [5]. Compounded semaglutide sodium or acetate salt forms are not the same as the free-base semaglutide used in clinical trials. The FDA's March 2024 guidance document on compounded semaglutide explicitly states that semaglutide sodium is not the same active ingredient as semaglutide in FDA-approved products.

Dr. Robert Kushner, Northwestern University, stated in a 2024 Obesity Society position statement: "Patients using compounded semaglutide or tirzepatide should be monitored with the same clinical rigor as those on brand-name products, including regular HbA1c, weight, and adverse-event tracking."

Clinicians prescribing compounded GLP-1 agents through telehealth should document the clinical rationale, confirm 503B pharmacy registration status, and schedule follow-up at 4 and 12 weeks to assess response and tolerability per AACE obesity guidelines [8].

Frequently Asked Questions